-
1
-
-
0031920799
-
Cancer phase i clinical trials: Efficient dose escalation with overdose control
-
Babb J, Rogatko A, Zacks S (1998) 'Cancer phase I clinical trials: efficient dose escalation with overdose control'. Stat Med 17(10): 1103-1120.
-
(1998)
Stat Med
, vol.17
, Issue.10
, pp. 1103-1120
-
-
Babb, J.1
Rogatko, A.2
Zacks, S.3
-
2
-
-
77951296573
-
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
-
Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M (2010) 'Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer'. Breast Cancer Res Treat 121(1): 121-131.
-
(2010)
Breast Cancer Res Treat
, vol.121
, Issue.1
, pp. 121-131
-
-
Barrios, C.H.1
Liu, M.C.2
Lee, S.C.3
Vanlemmens, L.4
Ferrero, J.M.5
Tabei, T.6
Pivot, X.7
Iwata, H.8
Aogi, K.9
Lugo-Quintana, R.10
Harbeck, N.11
Brickman, M.J.12
Zhang, K.13
Kern, K.A.14
Martin, M.15
-
3
-
-
26844452967
-
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
-
Boccadoro M, Morgan G, Cavenagh J (2005) 'Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy'. Cancer Cell Int 5(1): 18.
-
(2005)
Cancer Cell Int
, vol.5
, Issue.1
, pp. 18
-
-
Boccadoro, M.1
Morgan, G.2
Cavenagh, J.3
-
4
-
-
78049462514
-
Phase II study of daily sunitinib in FDG-PETpositive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation
-
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG (2010) 'Phase II study of daily sunitinib in FDG-PETpositive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation'. Clin Cancer Res 16(21): 5260-5268.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.21
, pp. 5260-5268
-
-
Carr, L.L.1
Mankoff, D.A.2
Goulart, B.H.3
Eaton, K.D.4
Capell, P.T.5
Kell, E.M.6
Bauman, J.E.7
Martins, R.G.8
-
5
-
-
53149115608
-
A phase i and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
-
Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ (2008) 'A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors'. Cancer Chemother Pharmacol 63(1): 99-107.
-
(2008)
Cancer Chemother Pharmacol
, vol.63
, Issue.1
, pp. 99-107
-
-
Dees, E.C.1
O'Neil, B.H.2
Lindley, C.M.3
Collichio, F.4
Carey, L.A.5
Collins, J.6
Riordan, W.J.7
Ivanova, A.8
Esseltine, D.9
Orlowski, R.Z.10
-
6
-
-
65549125308
-
Phase i study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
-
Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P (2009) 'Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor'. Br J Cancer 100(9): 1379-1384.
-
(2009)
Br J Cancer
, vol.100
, Issue.9
, pp. 1379-1384
-
-
Dudek, A.Z.1
Lesniewski-Kmak, K.2
Shehadeh, N.J.3
Pandey, O.N.4
Franklin, M.5
Kratzke, R.A.6
Greeno, E.W.7
Kumar, P.8
-
7
-
-
36749052895
-
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
-
Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) 'Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy'. Proc Natl Acad Sci USA 104(43): 17069-17074.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, Issue.43
, pp. 17069-17074
-
-
Ebos, J.M.1
Lee, C.R.2
Christensen, J.G.3
Mutsaers, A.J.4
Kerbel, R.S.5
-
8
-
-
33750945704
-
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
-
Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006) 'Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer'. J Clin Oncol 24(31): 5025-5033.
-
(2006)
J Clin Oncol
, vol.24
, Issue.31
, pp. 5025-5033
-
-
Fanucchi, M.P.1
Fossella, F.V.2
Belt, R.3
Natale, R.4
Fidias, P.5
Carbone, D.P.6
Govindan, R.7
Raez, L.E.8
Robert, F.9
Ribeiro, M.10
Akerley, W.11
Kelly, K.12
Limentani, S.A.13
Crawford, J.14
Reimers, H.J.15
Axelrod, R.16
Kashala, O.17
Sheng, S.18
Schiller, J.H.19
-
9
-
-
77950474660
-
Phase II study of sunitinib in patients with metastatic urothelial cancer
-
Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Boyle MG, Trout A, Flaherty AM, Bajorin DF (2010) 'Phase II study of sunitinib in patients with metastatic urothelial cancer'. J Clin Oncol 28(8): 1373-1379.
-
(2010)
J Clin Oncol
, vol.28
, Issue.8
, pp. 1373-1379
-
-
Gallagher, D.J.1
Milowsky, M.I.2
Gerst, S.R.3
Ishill, N.4
Riches, J.5
Regazzi, A.6
Boyle, M.G.7
Trout, A.8
Flaherty, A.M.9
Bajorin, D.F.10
-
10
-
-
77649322923
-
Safety and efficacy of combining sunitinib with bevacizumabpaclitaxel/ carboplatin in non-small cell lung cancer
-
Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF (2010) 'Safety and efficacy of combining sunitinib with bevacizumabpaclitaxel/carboplatin in non-small cell lung cancer'. J Thorac Oncol 5(3): 354-360.
-
(2010)
J Thorac Oncol
, vol.5
, Issue.3
, pp. 354-360
-
-
Socinski, M.A.1
Scappaticci, F.A.2
Samant, M.3
Kolb, M.M.4
Kozloff, M.F.5
-
11
-
-
84866026922
-
Blockade of NFkappaB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells
-
Sorolla A, Yeramian A, Valls J, Dolcet X, Bergada L, Llombart-Cussac A, Mart? RM, Matias-Guiu X (2012) 'Blockade of NFkappaB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells'. Mol Oncol 6(5): 530-541.
-
(2012)
Mol Oncol
, vol.6
, Issue.5
, pp. 530-541
-
-
Sorolla, A.1
Yeramian, A.2
Valls, J.3
Dolcet, X.4
Bergada, L.5
Llombart-Cussac, A.6
Mart, R.M.7
Matias-Guiu, X.8
-
12
-
-
78650229308
-
Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
-
Tighiouart M, Rogatko A (2010) 'Dose finding with escalation with overdose control (EWOC) in cancer clinical trials'. Stat Sci 25: 217-226.
-
(2010)
Stat Sci
, vol.25
, pp. 217-226
-
-
Tighiouart, M.1
Rogatko, A.2
-
13
-
-
0642349188
-
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts
-
Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ (2003) 'Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts'. Mol Cancer Ther 2(9): 835-843.
-
(2003)
Mol Cancer Ther
, vol.2
, Issue.9
, pp. 835-843
-
-
Williams, S.1
Pettaway, C.2
Song, R.3
Papandreou, C.4
Logothetis, C.5
McConkey, D.J.6
-
14
-
-
77955729630
-
Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy
-
Wright JJ (2010) 'Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy'. Clin Cancer Res 16(16): 4094-4104.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.16
, pp. 4094-4104
-
-
Wright, J.J.1
-
15
-
-
83955161761
-
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway
-
Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Mart?RM (2012) 'Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway'. Int J Cancer 130(4): 967-978.
-
(2012)
Int J Cancer
, vol.130
, Issue.4
, pp. 967-978
-
-
Yeramian, A.1
Sorolla, A.2
Velasco, A.3
Santacana, M.4
Dolcet, X.5
Valls, J.6
Abal, L.7
Moreno, S.8
Egido, R.9
Casanova, J.M.10
Puig, S.11
Vilella, R.12
Llombart-Cussac, A.13
Matias-Guiu, X.14
Marti, R.M.15
|